Treatment Strategies and Management Plan

Managing PCDH19-related epilepsy is a balance between daily prevention and being prepared for sudden clusters. Because every child’s genetic makeup and brain chemistry are slightly different, there is no single universally reliable first-line medication for this condition. Instead, doctors often look for a combination of treatments that work best for your child’s unique needs, based on observational evidence ^[1][2].

Important: Never change or stop any medication without direct instruction from the prescriber.

Daily Preventive Medications

The goal of daily anti-seizure medications (ASMs) is to reduce the frequency and intensity of clusters. While research is still ongoing, certain medications are frequently used as individualized options:

• Levetiracetam: This is often one of the options tried and has shown seizure reduction in some observational groups ^[1][3]. Safety Note: It can worsen irritability or behavior, which must be carefully monitored.
• Clobazam: This medication belongs to the benzodiazepine family but is taken daily. It is used to help stabilize the brain’s electrical activity ^[1][2]. Safety Note: It can cause significant sedation, and patients may build a tolerance over time.
• Potassium Bromide: While less common in general epilepsy, this “older” medication is sometimes used in PCDH19 ^[1][2]. Safety Note: It carries specific toxicity risks, requires regular monitoring, and has region-specific availability considerations.
• Valproate: This is another commonly used agent ^[3][1]. Safety Note: Valproate carries major risks for liver and pancreas toxicity. Crucially, it has severe reproductive and fetal risks (teratogenicity) if taken during pregnancy, requiring strict monitoring and counseling for anyone who may become pregnant.

Medications to Approach with Caution

In some types of epilepsy, medications called sodium channel blockers (such as carbamazepine or oxcarbazepine) are very effective. However, in PCDH19, these drugs can sometimes be ineffective or even make seizures worse for some children ^[1]. While not uniformly contraindicated without specialist advice, the reaction to these drugs can vary from patient to patient, so discuss these risks with your neurologist ^[4][5].

The Critical Role of a Rescue Plan

Because PCDH19 is defined by clusters—seizures that happen one after another—having a daily medication is often not enough. You must have an individualized, written Seizure Action Plan (SAP) ^[6].

This plan is your “emergency manual” and should include:

1. A Cluster Definition: Exactly what counts as a cluster for your child (for example, “3 seizures in 24 hours”). This ensures you know exactly when to intervene ^[6][7].
2. Rescue Medication and Route: A fast-acting drug designed to stop a cluster.
   • Midazolam may be prescribed as an intranasal (in the nose) spray or buccal (inside the cheek) liquid.
   • Diazepam may be prescribed rectally or intranasally.
   • Never put standard oral medication (pills or liquid) in the mouth during a seizure or impaired awareness ^[6][7].
3. Dosing Instructions: Exactly how much to give, prescribed routes, and when it is safe to give a second dose. Because benzodiazepine rescue medications can cause marked sedation or breathing problems, explicit breathing monitoring instructions are critical ^[6].
4. Emergency Thresholds: Clear instructions on when to stop home treatment and call for emergency medical services (such as if a seizure lasts more than 5 minutes or if the rescue medication doesn’t work) ^[6][7].

Investigational Treatments: Ganaxolone

You may hear about a medication called ganaxolone. This drug targets the GABA receptors in the brain ^[8].

A clinical trial (the VIOLET study) looked at whether ganaxolone could help reduce seizure frequency in PCDH19 ^[9]. While some children in the study saw a decrease in seizures, the results did not reach the level of statistical significance, meaning ganaxolone is not currently approved for PCDH19-related epilepsy, though it is approved for other specific conditions like CDKL5 deficiency disorder ^[9][10]. It remains an investigational or off-label option, and your doctor can help you verify trial access and weigh potential benefits and side effects ^[9].

A Long-Term Perspective

It is important to know that PCDH19 is a “marathon, not a sprint.” While seizure clusters are often most intense in childhood, many patients see a decrease in seizure frequency as they get older ^[11]. However, even if your child has been seizure-free for a long time, doctors usually advise against stopping medications abruptly, as the risk of seizures returning can be high ^[12]. Always work closely with your epileptologist (an epilepsy specialist) before making any changes to the treatment plan.